The reSET mHealth platform is available for healthcare providers to prescribe to their patients.
A mHealth substance abuse treatment app called reSET is the first digital therapeutic treatment for substance abuse disorder to be granted approval by the U.S. Food and Drug Administration (FDA). This unique digital treatment platform can now be prescribed to patients by their medical providers.
The prescription-based digital therapeutic offers a 12-week treatment plan.
Developed by Pear Therapeutics, the mHealth substance abuse treatment app offers patients a 90-day (12-week) treatment plan. The plan features interactive treatment modules. These modules deliver cognitive behavioral therapy and fluency training to reinforce proficiency.
“reSET has been clinically validated to significantly improve outcomes for patients, while also providing patients a discreet way to access care when and where they need it,” stated Pear Therapeutics Preside and CEO Corey McCann, MD, PhD in a recent press release announcing the launch of the app as a treatment for patients with Substance Use Disorder (SUD).
“Prescription digital therapeutics will help redefine the treatment of serious diseases like Substance Use Disorder, providing improved patient outcomes, and driving clinical insights for clinicians,” McCann added.
Beyond its mHealth substance abuse treatment app, the company has plans for other digital therapies.
In addition to reSET, Pear Therapeutics has also created a separate prescription digital therapeutic designed for treating Opioid Use Disorder. Although not yet approved by the FDA, this digital therapy was granted Expedited Access Pathway designation in October 2017 and is presently under review by the FDA.
What’s more, earlier this year, the company announced that it had partnered with Sandoz, a division of Novartis, to commercialize both reSET and reSET-O. Additionally, the two companies have reportedly announced plans to develop new digital treatments for multiple sclerosis and schizophrenia.
The reSET mHealth app has received FDA approval for prescription use only as an adjunct treatment for patients with SUD who do not abuse only alcohol, who are not currently on opioid replacement therapy, or whose main substance of abuse is not opioids.
The mHealth substance abuse treatment app is intended to be used in conjunction with outpatient therapy and in addition to a contingency management system. This system is a program widely used for the treatment of SUD and uses a series of incentives to reward patience for adhering to their treatment program.